Vaxart, Inc. (NASDAQ: VXRT)

Introduction

As of June 11, 2025, Vaxart, Inc. (ticker: VXRT) is trading at $0.5517, reflecting a 40.42% increase from its previous close, with a trading volume of 16,624,174 shares on the NASDAQ. Vaxart is a clinical-stage biotechnology company focused on the development of oral recombinant vaccines aimed at eliciting both mucosal and systemic immunity against viral diseases.

Corporate Structure

• Incorporation: Founded in 2004 as West Coast Biologicals, Inc.; renamed Vaxart, Inc. in July 2007 after reincorporating in Delaware.
• Headquarters: South San Francisco, California
• Employees: 51–200
• Leadership:
  • Sean Tucker, Founder & Chief Scientific Officer
  • Jeroen Grasman, Chief Financial Officer (appointed May 19, 2025)

Developments and News

Clinical Progress

• June 11, 2025: Data presentation demonstrated that second-generation norovirus constructs produced a 141% increase in GI.1 and a 94% increase in GII.4 blocking antibodies compared to first-generation constructs. No vaccine-related serious adverse events were reported.
• 2025: Vaxart began dosing the first patient in the 10,000-participant portion of its Phase 2b oral COVID-19 vaccine trial, following approval from the Biomedical Advanced Research and Development Authority (BARDA).
• Mid-2025: Topline data from the norovirus program is anticipated.

Corporate Actions

• May 20, 2025: The Compensation Committee granted equity awards to CFO Jeroen Grasman, including:
  • An option to purchase 1,000,000 shares of common stock
  • Restricted stock units covering 350,000 shares
• May 29, 2025: Vaxart filed proxy materials proposing a reverse stock split to meet NASDAQ’s minimum bid price rule, requesting stockholder votes by June 1, 2025.
• June 2, 2025: Filed Form 8-K reporting stockholder vote results, Regulation FD disclosures, and financial statements and exhibits.

Partnerships and Grants

• January 2024: Vaxart was awarded a grant totaling $9.27 million from BARDA to support its oral COVID-19 vaccine candidate's development.

Financial and Strategic Analysis

Metric	Value
Share Price (6/11/2025)	$0.5517
Daily Volume	16,624,174
52-Week Range	$0.28 – $1.07
Market Cap	$89.67 M
Enterprise Value	$64.56 M
Price/Sales (TTM)	1.82
Price/Book (MRQ)	1.99
Revenue (TTM)	$47.4 M
Net Income (TTM)	-$58.12 M
Diluted EPS (TTM)	-0.26
Total Cash (MRQ)	$41.94 M
Debt/Equity (MRQ)	45.07%
Levered Free Cash Flow (TTM)	$50.39 M

• The company is currently unprofitable, with a profit margin of -122.63% and negative earnings per share.
• Liquidity is supported by $41.94 million in cash against a moderate debt level.

Market Position and Industry Context

• Platform Technology: The company employs oral vaccine tablets utilizing an Ad5 vector combined with enteric coating to stimulate both systemic and mucosal immunity.
• Pipeline: Vaxart is developing vaccine candidates aimed at norovirus, seasonal influenza, respiratory syncytial virus, human papillomavirus, COVID-19, and therapeutic vaccines for oncology.
• Competitive Landscape: The company faces competition from other injectable and oral vaccine developers, including Novavax, Inovio, and Moderna.
• Advantages: Vaxart's temperature-stable, needle-free delivery system could potentially enhance distribution capabilities and improve patient acceptance.

tl;dr

• On June 11, 2025, VXRT increased by 40.42% to $0.5517.
• Clinical data indicated significant increases in norovirus antibody responses with no serious adverse events reported.
• The Phase 2b oral COVID-19 vaccine trial dosing commenced under BARDA support.
• CFO Jeroen Grasman received equity awards on May 20, 2025, and a reverse stock split was proposed in proxy materials filed on May 29, 2025.
• Topline data from the norovirus program is expected in mid-2025.